Single-Dose Cisplatin Pre-Treatment Enhances Efficacy of ROBO1-Targeted Radioimmunotherapy

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Cancer Research

Background:

• Radioimmunotherapy (RIT) using ⁹⁰Y-labeled anti-ROBO1 IgG (⁹⁰Y-B5209B) showed anti-tumor effects in small-cell lung cancer (SCLC) xenografts.
• Tumor regrowth after initial RIT indicated a need for enhanced therapeutic strategies.

Purpose of the Study:

• To evaluate the efficacy of combining ⁹⁰Y-B5209B RIT with cisplatin in NCI-H69 SCLC xenograft mice.
• To determine if cisplatin pre-treatment enhances the therapeutic effect of ⁹⁰Y-B5209B.

Main Methods:

• Mice with SCLC xenografts were divided into four groups: saline, cisplatin only, RIT only, or combination therapy.
• Cisplatin was administered one day prior to saline or ⁹⁰Y-B5209B.
• Tumor volume, body weight, blood cell counts, and survival duration were monitored.

Main Results:

• Combination therapy significantly prolonged survival compared to RIT alone.
• Cisplatin monotherapy did not show a significant survival benefit.
• Combination therapy induced more significant pathological changes than RIT alone.
• Adverse effects like weight loss and pancytopenia were observed but were transient.

Conclusions:

• Cisplatin pre-treatment can enhance the efficacy of ⁹⁰Y-B5209B RIT for SCLC.
• The combination of ⁹⁰Y-B5209B and cisplatin represents a promising therapeutic strategy for SCLC.
• Further investigation into this combination therapy is warranted for SCLC treatment.